Anebulo Pharmaceuticals IncNASDAQ:ANEB
- LAST PRICE2.3700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.1100/ 1
- Ask / Lots2.7500/ 5
- Open / Previous Close2.4232 / 2.3700
- Day Range
- 52 Week Range
- Volume2,548
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ANEB |
|---|---|---|
| 10:20 ET | 699 | 2.4232 |
| 03:35 ET | 100 | 2.28 |
| 03:39 ET | 125 | 2.27 |
| 03:42 ET | 100 | 2.275 |
| 03:51 ET | 573 | 2.37 |
Nov 14, 2023
Press Release: Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates, from 4:08PM ET on Tuesday Nov 14, 2023 by Dow Jones
4:08PM ET on Tuesday Nov 14, 2023 by Dow JonesAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates, from 4:05PM ET on Tuesday Nov 14, 2023 by Dow Jones
4:05PM ET on Tuesday Nov 14, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Anebulo Pharmaceuticals Inc | 60.8M | -5.2x | --- |
Spruce Biosciences Inc | 60.7M | -1.0x | --- |
Tiziana Life Sciences Ltd | 60.9M | -4.0x | --- |
Kezar Life Sciences Inc | 60.9M | -0.7x | --- |
Mural Oncology PLC | 61.1M | -0.3x | --- |
Leap Therapeutics Inc | 59.8M | -0.4x | --- |
Company Information
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The Company’s lead product candidate is ANEB-001, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat ACI. ANEB-001 is an orally bioavailable, rapidly absorbed treatment that it anticipates is rapidly reverse the symptoms of ACI and reduce the time to recovery. The signs and symptoms of ACI range from profound sedation to anxiety and panic to psychosis with hallucinations. CB1 receptors are concentrated in the brain and central nervous system, while CB2 receptors are found in peripheral organs and are associated with the immune system.
Contact Information
- Headquarters
- Jfl Capital Management 1017 Rr 620 S, Suite 107LAKEWAY, TX, United States 78734
- Phone
- 512-598-0931
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $60.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.45 |
Book Value | $0.41 |
P/E Ratio | -5.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
